NASDAQ:OGIOrganiGram Stock Price, Forecast & News

OrganiGram's stock was trading at $1.72 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, OGI stock has increased by 4.7% and is now trading at $1.80. View which stocks have been most impacted by Coronavirus.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OrganiGram in the last year. There are currently 6 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for OrganiGram.

OrganiGram is scheduled to release its next quarterly earnings announcement on Monday, July 20th 2020. View our earnings forecast for OrganiGram.

OrganiGram Holdings Inc (NASDAQ:OGI) posted its earnings results on Tuesday, April, 14th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.01) by $0.01. The company had revenue of $27.30 million for the quarter, compared to analyst estimates of $25.07 million. OrganiGram had a negative return on equity of 5.33% and a negative net margin of 45.14%. The business's revenue was down 18.3% on a year-over-year basis. View OrganiGram's earnings history.

12 Wall Street analysts have issued 12 month target prices for OrganiGram's shares. Their forecasts range from $1.72 to $12.00. On average, they anticipate OrganiGram's stock price to reach $6.46 in the next twelve months. This suggests a possible upside of 259.0% from the stock's current price. View analysts' price targets for OrganiGram.

News articles about OGI stock have been trending negative on Thursday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. OrganiGram earned a news impact score of -2.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutOrganiGram.

OrganiGram saw a increase in short interest in April. As of April 30th, there was short interest totaling 12,120,000 shares, an increase of 33.5% from the April 15th total of 9,080,000 shares. Based on an average trading volume of 3,748,600 shares, the short-interest ratio is presently 3.2 days. Approximately 7.1% of the company's stock are sold short. View OrganiGram's Current Options Chain.

Some companies that are related to OrganiGram include Kiniksa Pharmaceuticals (KNSA), Cytokinetics (CYTK), Supernus Pharmaceuticals (SUPN), Mersana Therapeutics (MRSN), Revance Therapeutics (RVNC), Phathom Pharmaceuticals (PHAT), I-Mab (ARQT), Esperion Therapeutics (ESPR), Aimmune Therapeutics (AIMT), Odonate Therapeutics (ODT), MacroGenics (MGNX), Phibro Animal Health (PAHC), Rocket Pharmaceuticals (RCKT), Enanta Pharmaceuticals (ENTA) and Applied Therapeutics (APLT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other OrganiGram investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Cronos Group (CRON), KushCo (KSHB), Aphria (APHA), Auxly Cannabis Group (CBWTF), Charlotte's Web (CWBHF), Innovative Industrial Properties (IIPR), NVIDIA (NVDA) and Alibaba Group (BABA).

OrganiGram trades on the NASDAQ under the ticker symbol "OGI."

OrganiGram's stock is owned by a variety of retail and institutional investors. Top institutional investors include ETF Managers Group LLC (6.72%), AdvisorShares Investments LLC (0.48%), Intact Investment Management Inc. (0.34%), CIBC World Markets Inc. (0.10%), Morgan Stanley (0.09%) and Jane Street Group LLC (0.08%).

OGI stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, CIBC World Markets Inc., Toronto Dominion Bank, Creative Planning, and Raymond James & Associates.

OGI stock was bought by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, Intact Investment Management Inc., Jane Street Group LLC, AdvisorShares Investments LLC, Advisor Group Holdings Inc., Sigma Planning Corp, Mission Wealth Management LP, and Mission Wealth Management LP.

Shares of OGI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OGI stock can currently be purchased for approximately $1.80.

OrganiGram has a market capitalization of $316.26 million and generates $61.27 million in revenue each year. The company earns $-7,200,000.00 in net income (profit) each year or $0.06 on an earnings per share basis. OrganiGram employs 615 workers across the globe.

The official website for OrganiGram is www.organigram.ca.

OrganiGram's mailing address is 35 English Dr., Moncton Z4, E1E 3X3. The company can be reached via phone at 1-855-961-9420.